Navigation Links
Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
Date:9/9/2008

Third PharmacoSurgery(TM) Platform Product Candidate in Clinical Trials

SEATTLE, Sept. 9 /PRNewswire/ -- Omeros Corporation today announced that it is enrolling patients in a Phase 1/Phase 2 study of OMS302, the Company's third PharmacoSurgery(TM) product candidate, for use during ophthalmologic surgery. At least 60 patients undergoing age-related cataract extraction with lens replacement are planned for enrollment in the study.

"With the initiation of this study, all three of Omeros' current PharmacoSurgery product candidates are now in the clinic," said Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "Each of the two agents in OMS302 is currently used individually and perioperatively during eye surgery. OMS302 combines these two agents and their pharmacologic activities into a single proprietary product candidate. With approximately three million cataract procedures performed annually in the U.S. alone, OMS302 is designed to address a large and growing market."

The Phase 1/Phase 2 trial is a randomized, double-blind, vehicle-controlled and parallel-assigned study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain, discomfort and inflammation following the procedure. OMS302 is added to standard irrigation solutions used in ophthalmologic surgery and is delivered directly to the eye during the operation.

PharmacoSurgery(TM) product candidates are proprietary combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. The lead product candidate in the PharmacoSurgery(TM) platform is OMS103HP, which is currently in two Phase 3 clinical programs evaluating its safety and ability to improve postoperative joint function and reduce pain following arthroscopic surgery. The urological PharmacoSurgery
'/>"/>

SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
2. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
3. CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
4. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
5. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
8. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
11. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 New-generation electronic ... highly portable and lightweight. Simultaneously, circuitry is increasing ... processing speed to which it performs at. Connecting ... electronics and military equipment, such as cameras or ... micro-circular and nano-circular connectors include custom cable designs ...
(Date:6/18/2013)... , June 18, 2013 Apama ... on the development of next-generation atrial fibrillation technologies, ... 8295902 by the US Patent and Trademark Office ... low profile electrode assemblies for use on expandable ... or other surgical procedures. "We are ...
(Date:6/17/2013)... , June 17, 2013 Vanda Pharmaceuticals ... additional data today at ENDO 2013, the Endocrine ... tasimelteon can entrain (synchronize) both melatonin and cortisol ... reset the master body clock and address the ... (Non-24).  The SET (Safety and Efficacy of Tasimelteon) ...
Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4
... China, April 19, 2011 /PRNewswire-Asia-FirstCall/ -- China Botanic ... ("China Botanic" or the "Company"), a developer, manufacturer ... Chinese medicines ("TCM") in China, today announced that ... owned subsidiary, Harbin Renhuang Pharmaceutical Co., Ltd ("Renhuang"), ...
... Henry Schein, Inc. (Nasdaq: HSIC ), the largest ... announced today that it will release its first quarter 2011 ... 3, 2011, and will provide a live webcast of its ... a.m. Eastern Daylight Time. Speakers on the call will include ...
Cached Medicine Technology:China Botanic Pharmaceutical Provides Update on Badger Oil Sales 2China Botanic Pharmaceutical Provides Update on Badger Oil Sales 3Henry Schein to Webcast First Quarter 2011 Conference Call Tuesday, May 3, at 10:00 a.m. EDT 2
(Date:6/18/2013)... research has shown that cancer cells have a much ... cells. Now, scientists at The University of Texas at ... a new strategy to combat lung cancer. , In ... PLOS ONE , UT Dallas researchers compared the ... lung cells taken from the same patient. , ...
(Date:6/18/2013)... at Case Western Reserve University,s College of Arts ... made available avatarsvirtual patientsto train speech-language pathologists. ... to evaluate speech-language disorders to practice using an ... because a diagnosis doesn,t have to be made ... studying to become speech-language pathologists have previously relied ...
(Date:6/18/2013)... 18, 2013 More than 1.1 million people ... HIV/AIDS, according to the Centers for Disease Control and Prevention ... infected. In support of National HIV Testing Day on June ... Insurance (SSDI) representation, the CDC and other organizations are ... The CDC reports about 50,000 new HIV infections each year. ...
(Date:6/18/2013)... The Elizabeth Glaser Pediatric AIDS Foundation ... U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to ... milestones in the global effort to eliminate pediatric HIV/AIDs. ... as of June 2013, one million babies globally have ... PEPFAR’s inception in 2003, EGPAF has been a key ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died from ... session of a silicone treatment for gluteus augmentation at Cuerpos ... performed by a mystery Venezuelan doctor in a center that ... Bernabe Vazquez of Bayshore Cosmetic Surgery , women suffering ... are not board certified is more common than people think. ...
Breaking Medicine News(10 mins):Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3
... May 2 (HealthDay News) -- The costs of treating and ... million a year, a new study finds. It also ... the mosquito-borne disease could save $5 in illness-related costs. ... by government (24 percent), insurance companies (22 percent) and employers ...
... a big fan of bacon or ham? Your genes might ... 70 percent of participants had two functional copies of a gene ... receptor is attuned to a compound in male mammals called androstenone, ... people were asked to smell pork. Those with either one or ...
... HealthDay Reporter , WEDNESDAY, May 2 (HealthDay News) -- ... woman to woman and can even change dramatically in ... new analysis reveals. The findings are likely ... infections that currently prevails among obstetricians and gynecologists. ...
... HealthDay Reporter , WEDNESDAY, May 2 (HealthDay News) -- ... to wipe out stray cancer cells, a treatment that comes with ... a safer, lower dose of radioactive iodine is just as effective ... that remain after surgery. The research also found that patients ...
... of California, Davis, are among 12 scientists selected to ... this year. The awards provide $100,000 of direct support ... videoconferencing equipment for periodic communications with the foundation and ... UC Davis Hartwell Foundation postdoctoral researcher with $50,000 per ...
... A pioneering approach to imaging breast cancer in mice has ... fails to attack tumors and keep cancer in check. This ... (UCSF), may help to reveal new approaches to cancer immunotherapy. ... month, the work shows that the body,s natural defenses trip ...
Cached Medicine News:Health News:Dengue Fever a Major Cost Burden in Puerto Rico 2Health News:Study Redefines What a Healthy Vagina Is 2Health News:Study Redefines What a Healthy Vagina Is 3Health News:Lower-Dose Radioiodine Effective Against Thyroid Cancer 2Health News:Lower-Dose Radioiodine Effective Against Thyroid Cancer 3Health News:Lower-Dose Radioiodine Effective Against Thyroid Cancer 4Health News:Biomedical researchers receive Hartwell Foundation awards 2Health News:Biomedical researchers receive Hartwell Foundation awards 3Health News:'Thin red line' around breast cancer 2Health News:'Thin red line' around breast cancer 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: